Centessa Pharmaceuticals plc (CNTA) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $39.80: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality; Negative price momentum.
Centessa Pharmaceuticals is a pre-revenue clinical-stage biotech developing OX2R agonist therapeutics for sleep-wake disorders, led by cleminorexton (Phase 2a) for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia, with 118 full-time employees as of year-end 2025.... Read more
Sell if holding. Engine safety override at $39.80: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 51 mid-range, Bollinger mid-band. Score 4.1/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 57d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: moderate.
About Centessa Pharmaceuticals plc
About Centessa Pharmaceuticals plc
Centessa Pharmaceuticals' clinical value is concentrated in cleminorexton (formerly ORX750), a selective OX2R agonist in the Phase 2a CRYSTAL-1 adaptive trial for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH). In November 2025, topline data from the 2-week crossover design showed cleminorexton achieved statistically significant mean sleep latency improvements versus placebo in NT1 (1.5 mg cohort, p=0.0026) and IH (2.0 mg cohort, p=0.0213). On March 31, 2026, Centessa entered a Transaction Agreement with Eli Lilly for $38 per share in cash plus contingent value rights of up to $9 per share, with closing expected in Q3 2026.
Centessa generates no product revenue; as a clinical-stage company with 118 full-time equivalent employees at December 31, 2025, it funds operations through equity raises. Beyond cleminorexton, the pipeline includes ORX142—a Phase 1 candidate with 184 participants dosed as of the March 4, 2026 data cutoff, demonstrating statistically significant dose-dependent improvements in mean sleep latency on the MWT—and ORX489, which entered Phase 1 during Q1 2026 following FDA IND clearance. The company licensed its LockBody conditional-antibody technology to Genmab in February 2025 for research against up to three targets. Centessa relies substantially on CROs and CMOs for clinical trial management and manufacturing. Competitors in the narcolepsy space include Alkermes (LUMRYZ), Harmony Biosciences (WAKIX), Jazz Pharmaceuticals (XYREM/XYWAV), Takeda, and Eisai.
Show full overview
The pending Lilly acquisition introduces a binary outcome for holders: $38 per share in cash plus CVRs contingent on clinical milestones, or—if the Transaction fails—a potential $63 million termination fee payable by Centessa, impaired management capacity, and difficulty maintaining relationships with CROs, investigators, and partners. The 10-K also identifies the new CEO transition—Mario Alberto Accardi, effective January 1, 2026, succeeding Saurabh Saha—as an additional execution risk during the critical Phase 2a period preceding the anticipated Lilly close.
See also: Healthcare · Biotechnology
From Centessa Pharmaceuticals plc's most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-06-15Recent Developments — Centessa Pharmaceuticals plc
Latest news
- NEWS Wells Fargo Downgrades Centessa Pharmaceuticals to Equal-Weight, Raises Price Target to $42 — benzinga Apr 20, 2026 negative
- NEWS Deal Dispatch: McCormick, Unilever Merge, Sysco Acquires Jetro Restaurant Depot For $29 Billion, QVC Considers Bankruptc — benzinga Apr 3, 2026 neutral
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMpipelineorexin program10-K Item 1A: 'A large proportion of our value may at any time reside in a limited number of our programs ... as we believe is currently the case in light of our focus on our orexin program'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $39.80: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: RSI 51 mid-range, Bollinger mid-band. Prior stop was $39.48. Score 4.1/10, moderate confidence.
Take-profit target: $39.18 (-1.5% upside). Prior stop was $39.48. Stop-loss: $39.48.
Target reached (-3.4% upside); Quality below floor (1.6 < 4.0).
Centessa Pharmaceuticals plc trades at a P/E of N/A (forward -22.2). TrendMatrix value score: 4.0/10. Verdict: Sell.
19 analysts cover CNTA with a consensus score of 3.7/5. Average price target: $44.
What does Centessa Pharmaceuticals plc do?Centessa Pharmaceuticals is a pre-revenue clinical-stage biotech developing OX2R agonist therapeutics for sleep-wake...
Centessa Pharmaceuticals is a pre-revenue clinical-stage biotech developing OX2R agonist therapeutics for sleep-wake disorders, led by cleminorexton (Phase 2a) for narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia, with 118 full-time employees as of year-end 2025. On March 31, 2026, the company signed a definitive agreement to be acquired by Eli Lilly for $38 per share plus contingent value rights of up to $9 per share.